Zoetis, Inc. Stock Plummets to New 52-Week Low of $114.47

Zoetis, Inc., a prominent player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 114.47 as of March 13, 2026. This decline marks a significant downturn for the stock, which has experienced a 35.35% decrease in value over the past year, contrasting sharply with the S&P 500's performance of 20.12% during the same period. Despite the recent price drop, Zoetis maintains a robust market capitalization of USD 58,034 million and demonstrates strong management efficiency, reflected in a return on equity of 80.42%. The company has shown a healthy ability to service its debt, evidenced by a low debt-to-EBITDA ratio of 1.22 times. Additionally, Zoetis has reported positive results for six consecutive quarters, with operating cash flow peaking at USD 2,929 million. The stock's price-to-earnings ratio stands at 26.00, while its price-to-book ratio is 17.42. Despite the current challenges, Zoetis has achieved an annual net sales growth rate of 8.16%, indicating potential for long-term stability in its financial performance.